News

Manufacturing Chemist | Multidimensional data analysis platforms: meeting new FDA calls for consistent evidence from CGT developers

Recent news that the US Food and Drug Administration (FDA) will ask cell and gene therapy (CGT) developers to provide more consistent evidence with their submissions has resulted in drug makers delaying development plans — and working on new ways to address the agency’s concerns

whitepages icon x

insideBIGDATA || Big Data in Life Sciences – Why ‘doing things the old way’ is the Biggest Barrier to Progress

Zachary Pitluk, Ph.D., Vice President of Life Sciences and Healthcare at Paradigm4, highlights how real insight comes, not from data collection, but from intelligent data curation, computation, and application.

whitepages icon x

European Pharmaceutical manufacturer || Paradigm4 and Alnylam partnership to accelerate RNAi- based drug discovery

Paradigm4’s REVEAL Integrative Analytics platform enables Alnylam Pharmaceuticals to discover novel, genetically-validated drug targets from population scale biobank genotype-phenotype datasets and underlies the pace and productivity of Alnylam’s RNAi therapeutics pipeline.

whitepages icon x

International Pharmaceutical Technology | 1 Trillion Cells, 50 Million Individuals

Calculating the true value of scientific data storage platforms is the goal of every developer. With millions of cells to analyze, digital solutions are the key